Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic illness that is characterized by recurring exacerbations. Exacerbations lead to the progression of the disease with development of respiratory failure, decreasing of the quality of life of the patient and, in severe cases, causing patient’s death. In the article we review the diagnostics of COPD and evidence base data on the treatment of exacerbations of COPD.
-
1.
Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.) Практическое руководство по антиинфекционной химиотерапии. Смоленск: МАКМАХ, 2007. - 464 с.
-
2.
Miravitlles М. Exacerbations of chronic obstructive pulmonary disease when are bacteria important? Eur Respir J 2002; 20 (suppl. 36):9-19.
-
3.
Ruiz-Gonzalez A., Gimenez A., Gomez-Arbones X., et al. Open-label, randomized comparison trial of longterm outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology 2007; 12:117-21.
-
4.
Peifer G., Veyssier P., Zuck P. Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors. Europ Resp J 2003; 22 (suppl. 45):3558.
-
5.
Siempos I.I., Dimopoulos G., Korbila I.P., et al. Macrolides, quinolones, and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29:1127-37.
-
6.
Weiss L.R. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. ClinTher 2002; 24(9):1414-25.
-
7.
Peifer G., Veyssier P., Zuck P. Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors. Europ Resp J 2003, v.22 (Suppl.); 45:3558A.
-
8.
Zadeikis N. The safety and efficacy of short-course (3-5 day), 750 mg levofloxacin (LVX) for acute bacterial exacerbation of chronic bronchitis (ABECB). 100th International Conference of the American Thoracic Society. Abstract D22 Poster #516.
-
9.
Sethi S., Fogarty C., Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir Med 2004; 98:697-707.
-
10.
Wilson R., Schentag J.J. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24:639-52.
-
11.
Wilson R., Allegra L., Huchon G., et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibioic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125:953-64.
-
12.
Дворецкий Л. И., Дубровская Н. В., Грудинина С. А. и соавт. Левофлоксацин и макролиды при обострении хронического бронхита. Результаты длительного мониторинга больных. Инфекции и антимикробная терапия 2005; (1):20-7.
-
13.
Дубровская Н.В. «Клинический и микробиологический мониторинг больных с обострением хронического бронхита после антибактериальной терапии», М.2005, Автореферат канд. дисс.
-
14.
Anthonisen N.R., Manfreda J., Warren C.P.W., et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
-
15.
Pechere J.C. Modeling and predicting clinical оutcomes of antibiotic therapy. Infect Med 1998; 15 (Suppl.E):46-50.
-
16.
Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-71.
-
17.
Sethi S. Pathogenesis of bacterial exacerbations of COPD. J Chronic Obstructive Pul Dis 2006; 3:109-15.
-
18.
Anthonisen N.R. Bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med 2002; 347:526-7.